Sun. Jun 16th, 2024
A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

This paper focuses on the Pro10™ cell line, a new technology designed to enhance the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The Pro10™ cell line is a proprietary mammalian suspension technology that enables the scalable and robust production of rAAVs, addressing the challenges associated with large-scale manufacturing in AAV gene therapies. These cells have been fully characterized and licensed for gene therapy development by various biopharmaceutical companies.

The Pro10™ cells are at the core of Viralgen’s reliable and scalable rAAV vector manufacturing process. They have been specifically optimized for rAAV production and have successfully been scaled up to 2000L, showcasing consistent and reproducible cell growth rates. The cells have demonstrated similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes.

Viralgen utilizes these cells as a critical component in their platform process for manufacturing AAV vectors, significantly contributing to the production of innovative gene therapies. By using these cells, Viralgen has reduced process development time and costs, making it easier for biopharmaceutical companies to bring new therapies to market faster and more efficiently.

For more information about the HEK293 derived animal component-free suspension Pro10™ cell line, please access the full PDF detailing its properties and benefits.

By Aiden Nguyen

As a content writer at newscholarly.com, I delve into the realms of storytelling with the power of words. With a knack for research and a passion for crafting compelling narratives, I strive to bring forth engaging and informative articles for our readers. From decoding complex concepts to unraveling current events, I aim to captivate and educate through the art of writing. Join me on this journey as we explore the ever-evolving landscape of news and knowledge together.

Leave a Reply